Navigation Links
Fralex reaches 100th patient milestone in fibromyalgia study
Date:3/10/2008

- Interim analysis results expected in Q3 2008 -

TORONTO, March 10 /PRNewswire-FirstCall/ - Fralex Therapeutics Inc. (TSX:FXI) ("Fralex" or the "Company"), a medical technology company developing a non-invasive neuromodulation device, today announced the randomization of the 100th patient into the RELIEF study. RELIEF is a multi-centre, double-blind placebo-controlled randomized clinical trial designed to assess the safety and efficacy of Complex Neural Pulse (CNP(TM)) therapy for the relief of chronic pain associated with fibromyalgia.

The data from the first 100 patients will serve as input to an interim analysis ("IA") which will lead to a determination of the number of patients required - between 200 and 300 - to achieve statistical significance at the primary efficacy endpoint. Enrolment will not pause following the randomization of the 100th patient. The results of the IA are expected to be available in Q3 2008.

"The randomization of 100 patients into our pivotal RELIEF trial is a significant milestone for Fralex. Results of the interim analysis will allow us to predict the number of subjects required to achieve statistical significance," said Avi Grewal, President and CEO of Fralex. "We believe that our CNP therapy has the potential to be a safe and effective, non-drug, non-invasive treatment for pain associated with fibromyalgia. The information from the interim analysis will be critical for developing timelines for the commercialization of our CNP therapy."

The RELIEF trial is being conducted in the U.S. and Canada across 19 centres, under an Investigational Device Exemption ("IDE") from the U.S. FDA and an Investigational Testing Authorization ("ITA") from Health Canada. Patients are randomized on a one-to-one basis to receive CNP or placebo for 12 weeks. The primary efficacy endpoint will be a statistically significant difference between the active and placebo groups in the reduction of their Numerical Rating S
'/>"/>

SOURCE Fralex Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
2. Genmab Reaches Milestones in Ofatumumab Collaboration
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
5. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
6. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
7. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
8. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
9. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Artromick Aligns with McKesson to Enhance Medication Safety at the Patients Bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in ... industry, is asking industry professionals to prepare for fall ... E2 soap they’re currently using to the Best Sanitizers’ ... Hand hygiene is critical to fighting cross-contamination and the ... key criteria are identified to evaluate the effectiveness of ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Production of cellulosic ethanol in Scotland, S.D. to start in Q4 ... ... 2008 -- At the American Coalition for Ethanol conference, http://www.poet.com ... million pilot-scale cellulosic ethanol production facility later this year. The pilot ...
... 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 million, ... Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" or ... and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and,dietary-supplements, ...
... DuPont Tate & Lyle Bio Products today announced that its ... as a natural ingredient by ECOCERT®, one of the leading ... ... Loudon, TN August 13, 2008 –- http://www.duponttateandlyle.com/ ...
Cached Biology Technology:POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 2Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 3
(Date:8/28/2014)... traditional cigarettes, but still release toxins into the ... , Scientists studying secondhand smoke from e-cigarettes discovered ... particles, with close-to-zero exposure to organic carcinogens. However, ... second-hand e-cigarette smoke were found to be significantly ... of polycyclic aromatic hydrocarbons cancer-causing organic compounds ...
(Date:8/28/2014)... 2014) Researchers at the University of Minnesota have ... (FSHD) to be used for muscle regeneration research as ... for FSHD. , The research is published in the ... , There is no treatment for FSHD, which is ... of muscular dystrophy. FSHD is an unusual genetic disorder ...
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... of Sciences will honor 15 individuals with awards in recognition ... fields spanning the physical, biological, and medical sciences. The recipients ... Professor at the Pennsylvania State University, is the recipient of ... being honored for his innovative studies of the flow of ...
... applications as suspensions, engineers need to understand how to ... to understand DST and calculate when it will occur ... from consumer products to cement, a range of industries ... For simple liquids, such as water or ...
... and update of a controversial 20-year-old theory of consciousness ... that consciousness derives from deeper level, finer scale activities ... in "microtubules" inside brain neurons corroborates this theory, according ... They suggest that EEG rhythms (brain waves) also derive ...
Cached Biology News:Academy honors 15 for major contributions to science 2Academy honors 15 for major contributions to science 3Academy honors 15 for major contributions to science 4Academy honors 15 for major contributions to science 5CCNY team models sudden thickening of complex fluids 2Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness 2Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness 3
... Series are a line of pre-integrated ... fast and reliable automated solutions to ... "automation-friendly" building blocks, Caliper has created ... than conventional approaches, take up little ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
... The Mini-PROTEAN II multiscreen apparatus is used ... 7 cm) gels. The apparatus can screen up ... to cut the blot into strips. The apparatus ... templates that accommodate one or two 8 x ...
Biology Products: